Table 3 Distribution of the examined markers
N (%) | |
|---|---|
ER (n = 938) | |
Negative | 245 (26.1) |
Positive | 693 (73.9) |
PgR (n = 940) | |
Negative | 301 (32.0) |
Positive | 639 (68.0) |
Ki67 (n = 934) | |
Low | 299 (32.0) |
High | 635 (68.0) |
alphaB-crystallin (n = 940) | |
Negative | 770 (81.9) |
Weakly positive | 99 (10.5) |
Strongly positive | 71 (7.6) |
BRCA1 (n = 928) | |
Negative | 863 (93.0) |
Positive | 65 (7.0) |
BRCA1 (n = 86) | |
WT | 78 (90.7) |
Mutated | 8 (9.3) |
p53 (n = 918) | |
Negative | 445 (48.5) |
Positive | 473 (51.5) |
EGFR (n = 928) | |
Negative | 777 (83.7) |
Positive | 151 (16.3) |
CK5 (n = 923) | |
Negative | 802 (86.9) |
Positive | 121 (13.1) |
CK14 (n = 925) | |
Negative | 894 (96.6) |
Positive | 31 (3.4) |
CK17 (n = 909) | |
Negative | 884 (97.2) |
Positive | 25 (2.8) |